Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion

To assess the 12-month efficacy and safety profile of an individualized regimen of ranibizumab 0.5 mg driven by stabilization criteria in patients with macular edema secondary to central retinal vein occlusion (CRVO).